ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Ari O. Halldorsson
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Halldorsson, A. O.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Halldorsson, A. O.
Related Collections
Right arrow Myocardial protection
Right arrowRelated Article

Ann Thorac Surg 2002;73:581
© 2002 The Society of Thoracic Surgeons

Invited commentary

Ari O. Halldorsson, MDa

a Division of Cardiothoracic Surgery, Texas Tech University Health Sciences Center, 3601 4th St, Suite 3A111, Lubbock, TX 79430, USA

e-mail: ari.halldorsson@ttmc.ttuhsc.edu

This article describes a very well conducted animal study on the protective effects of a new poly (ADP-ribose) synthetase (PARS) inhibitor, PJ34, during myocardial ischemia and reperfusion injury. Dr Faro and coauthors can be congratulated on an excellent study using state of the art cardiovascular modalities and an equally well written manuscript. This study shows without a doubt that PARS inhibitors play a significant role in cell injury following ischemia-reperfusion and clinical studies are indicated following the excellent outcome of this experiment.

Poly (ADP-ribrose) synthetase is a nuclear enzyme that has been extensively investigated. It has been long known that PARS plays a significant role in apoptosis, but the exact mechanism by which it causes cell death, cellular differentiation, malignant transformation, gene amplification, and DNA replication is still being heavily investigated. During the 1970s and 1980s PARS received tremendous attention . . . [Full Text of this Article]


Related Article

Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor
Renato Faro, Yoshiya Toyoda, James D. McCully, Prakash Jagtap, Eva Szabo, Laszlo Virag, Cesario Bianchi, Sidney Levitsky, Csaba Szabo, and Frank W. Sellke
Ann. Thorac. Surg. 2002 73: 575-581. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2002 by The Society of Thoracic Surgeons.